Table 2.
Univariate and multivariate Cox proportional hazard regression analysis between clinicopathologic variables and progression-free survival
| Variable | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Disease status | ||||||
| Recurred | 1 | 1 | ||||
| Initial metastatic | 1.906 | 1.325-2.742 | 0.001 | 2.126 | 1.434-3.152 | < 0.001 |
| Pathology | ||||||
| ADC | 1 | - | ||||
| Non-ADC | 0.886 | 0.548-1.434 | 0.623 | - | - | - |
| Smoking | ||||||
| Never | 1 | - | ||||
| Current or ex-smoking | 1.237 | 0.880-1.739 | 0.220 | - | - | - |
| ECOG PS | ||||||
| 0-1 | 1 | 1 | ||||
| 2-4 | 1.740 | 1.088-2.783 | 0.021 | 1.978 | 1.210-3.235 | 0.007 |
| EGFR TKI | ||||||
| Gefitinib | 1 | - | ||||
| Erlotinib | 0.910 | 0.590-1.402 | 0.668 | - | - | - |
| Line | ||||||
| 1st | 1 | 1 | ||||
| 2nd | 1.270 | 0.908-1.777 | 0.163 | 1.233 | 0.860-1.767 | 0.254 |
| 3rd or more | 1.925 | 1.116-3.321 | 0.019 | 2.198 | 1.228-3.936 | 0.008 |
| EGFR mutation | ||||||
| Del-19 or L858R | 1 | - | ||||
| Rare | 4.158 | 2.358-7.331 | < 0.001 | - | - | - |
| Response to TKI | ||||||
| Responding | 1 | 1 | ||||
| Non-responding | 3.056 | 2.223-4.200 | < 0.001 | 3.141 | 2.228-4.426 | < 0.001 |
| Liver metastasis | ||||||
| No | 1 | - | ||||
| Yes | 1.546 | 1.067-2.240 | 0.021 | - | - | - |
| Bone metastasis | ||||||
| No | 1 | 1 | ||||
| Yes | 1.730 | 1.286-2.327 | < 0.001 | 1.384 | 1.001-1.913 | 0.049 |
| Brain metastasis | ||||||
| No | 1 | - | ||||
| Yes | 1.241 | 0.919-1.677 | 0.160 | - | - | - |
HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.